Pyrazoles

"Pyrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.

Descriptor ID	D011720
MeSH Number(s)	D03.383.129.539
Concept/Terms	Pyrazoles Pyrazoles

Below are MeSH descriptors whose meaning is more general than "Pyrazoles".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Azoles [D03.383.129]
Pyrazoles [D03.383.129.539]

Below are MeSH descriptors whose meaning is related to "Pyrazoles".

Below are MeSH descriptors whose meaning is more specific than "Pyrazoles".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Pyrazoles" by people in this website by year, and whether "Pyrazoles" was a major or minor topic of these publications.

Bar chart showing 87 publications over 24 distinct years, with a maximum of 9 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2001	0	1	1
2005	0	1	1
2006	0	2	2
2007	1	4	5
2008	1	5	6
2009	0	2	2
2010	2	0	2
2011	3	1	4
2012	1	1	2
2013	1	4	5
2014	0	3	3
2015	2	1	3
2016	1	1	2
2017	3	1	4
2018	3	5	8
2019	2	0	2
2020	4	5	9
2021	1	2	3
2022	1	3	4
2023	0	4	4
2024	1	1	2
2025	3	3	6
2026	0	6	6

Below are the most recent publications written about "Pyrazoles" by people in Profiles.

Weiner SD, Liang LW, Masri A, Abraham TP, Barriales-Villa R, Cooper RM, Elliott PM, de Feria A, Maron MS, Oreziak A, Saberi S, Solomon SD, Spertus JA, Tower-Rader A, Butzner M, Godown J, Heitner SB, Jacoby DL, Kupfer S, Liu X, Malik FI, Melloni C, Simkins TJ, Wei J, Nassif ME, Owens AT. Long-term impact of aficamten on patient-reported outcome measures in obstructive hypertrophic cardiomyopathy: results from FOREST-HCM. Eur J Heart Fail. 2026 Oct 28; 28(4):819-830.

View in: PubMed
Hegde SM, Wang X, Bhatia A, Peña-Peña ML, Sherrid MV, Figueiredo EL, Arad M, Barriales-Villa R, Choudhury L, Claggett BL, Coats CJ, de Barros Correia E, Costabel JP, Elliott PM, Silva Enciso JE, Garcia-Pavia P, Ge J, Ho CY, Lakdawala NK, Lewis GD, Maron MS, Martinez MW, Masri A, Maurer MS, Michels M, Mitter SS, Pino Moreno JE, Nagy V, Olivotto I, Owens AT, Poulsen SH, Rader F, Rowin EJ, Ruda M, Schulze PC, Sikand N, Spertus JA, Zhao X, Divanji PH, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Salazar-Mendiguchía J, Wohltman A, Zhuo S, Solomon SD. Effect of Aficamten on Cardiac Structure and Function in Patients With Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. Circulation. 2026 Oct 20; 154(16):1563-1576.

View in: PubMed
Maron MS, Masri A, Bhatia A, Peña-Peña ML, Sherrid MV, Figueiredo EL, Arad M, Choudhury L, Claggett BL, Coats CJ, de Barros Correia E, Costabel JP, Elliott PM, Silva Enciso JE, Ge J, Ho CY, Kulac I, Lewis GD, Martinez MW, Maurer MS, Michels M, Mitter SS, Pino Moreno JE, Olivotto I, Owens AT, Poulsen SH, Rader F, Rowin EJ, Schulze PC, Sepp R, Sikand N, Solomon SD, Spertus JA, Zhao X, Divanji PH, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Salazar-Mendiguchía J, Wohltman A, Zhuo S, Barriales-Villa R. Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM. Circulation. 2026 Oct 20; 154(16):1547-1559.

View in: PubMed
Lewis GD, Garcia-Pavia P, Masri A, Merkely B, Nassif ME, Peña-Peña ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, de Barros Correia E, Dybro AM, Kulac IJ, Lakdawala NK, Mann A, Maron MS, McGinnis S, Nair A, Newlands C, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Elliott PM. Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial. JAMA Cardiol. 2026 Aug 01; 11(8):736-746.

View in: PubMed
Tower-Rader A, Masri A, Nassif ME, Abraham TP, Barriales-Villa R, Choudhury L, Cooper RM, Elliott PM, Maron MS, Olivotto I, Oreziak A, Owens AT, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Liu X, Malik FI, Melloni C, Simkins TJ, Wei J, Saberi S. Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. Eur Heart J. 2026 Jun 23; 47(24):3120-3131.

View in: PubMed
Veselka J, Gimeno R, Abraham TP, Barriales-Villa R, Claggett BL, Coats CJ, Hegde SM, Januzzi JL, Masri A, Miao ZM, Nassif ME, Olivotto I, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Maron MS. Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients. Am J Cardiol. 2026 Jul 01; 270:133-141.

View in: PubMed
Garcia-Pavia P, Maron MS, Masri A, Merkely B, Nassif ME, Peña-Peña ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, Correia EB, Dybro AM, Elliott P, Hegde SM, Lakdawala NK, Lewis GD, Mann A, Miao ZM, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025 Sep 11; 393(10):949-960.

View in: PubMed
Litman HJ, Sheffield KM, Pugach O, Shan M, Lakin P, Cui ZL, Curtis SE, Johnston JA, Harrold LR. Applying Bias Correction Methods to Build Hybrid Controls Using Real-World Patients for a Phase IIb Randomized Controlled Trial of Baricitinib for Rheumatoid Arthritis. Pharm Stat. 2025 Jul-Aug; 24(4):e70020.

View in: PubMed
Maron MS, Gimeno JR, Veselka J, Barriales-Villa R, Claggett BL, Coats CJ, Hegde SM, Januzzi JL, Kulac IJ, Masri A, Nassif ME, Spertus JA, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Olivotto I. Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. Eur Heart J. 2025 10 22; 46(40):4076-4086.

View in: PubMed
Hasanvand A, Ghandinezhad M, Nourmohammadi M, Hatami F, Beiranvand B, Haghighatian Z, Amanolahi Baharvand P, Kharazmkia A. Investigating the role of the AMPK signaling pathway in preventing CCI-induced neuropathy in rats: focus on anti-inflammatory effects. Neurol Res. 2025 Jun; 47(6):494-503.

View in: PubMed

People

Explore

Similar Concepts

Top Journals